Laxxon Medical
Developer of additive manufacturing methods for oral drug delivery. Focus areas include screen-printing additive manufacturing for small-batch R&D through industrial-scale production, formulation design for immediate/delayed/extended and sequential release, technology transfer to CDMOs for cGMP manufacture, regulatory pathway planning (including FDA 505(b)(2) and EU hybrid routes), and an in-house and partnered pipeline of printed oral dosage forms.
Industries
Nr. of Employees
small (1-50)
Laxxon Medical
261 Madison Ave, New York, NY 10016
Patents
Products
Oral GLP-1 agonist formulation (preclinical program)
Oral peptide formulation program using printing-based manufacturing and permeation enhancers to enable oral delivery of a GLP-1 receptor agonist (program funded for development).
Extended-release levodopa/carbidopa formulation (development program)
Printed oral levodopa/carbidopa formulation designed for extended release with pilot PK data reported.
Collaborative modified-release oral formulations
Externally partnered development projects producing modified-release oral formulations using screen-printing technology.
Portfolio of in-house and partnered printed assets
A pipeline of internal and partnered printing-based products across multiple therapeutic areas, intended for R&D and partner licensing.
Oral GLP-1 agonist formulation (preclinical program)
Oral peptide formulation program using printing-based manufacturing and permeation enhancers to enable oral delivery of a GLP-1 receptor agonist (program funded for development).
Extended-release levodopa/carbidopa formulation (development program)
Printed oral levodopa/carbidopa formulation designed for extended release with pilot PK data reported.
Collaborative modified-release oral formulations
Externally partnered development projects producing modified-release oral formulations using screen-printing technology.
Portfolio of in-house and partnered printed assets
A pipeline of internal and partnered printing-based products across multiple therapeutic areas, intended for R&D and partner licensing.
Services
Transfer of screen-printing manufacturing processes to industrial partners or CDMOs to enable commercial supply and to support reformulation strategies for patent extension.
Development of differentiated generic or repurposed oral products using additive manufacturing to create tailored release profiles and pursue expedited regulatory routes.
End-to-end R&D and prototyping of novel oral assets using multi-material and geometry-based approaches to achieve targeted release and patient-centric dosage forms.
Advisory services on regulatory pathway selection (e.g., 505(b)(2), EU hybrid) and patent filing/portfolio management for printing-based dosage forms.
Operational support and partnerships to secure cGMP clinical and commercial production capacity for printed oral dosage forms.
Transfer of screen-printing manufacturing processes to industrial partners or CDMOs to enable commercial supply and to support reformulation strategies for patent extension.
Development of differentiated generic or repurposed oral products using additive manufacturing to create tailored release profiles and pursue expedited regulatory routes.
End-to-end R&D and prototyping of novel oral assets using multi-material and geometry-based approaches to achieve targeted release and patient-centric dosage forms.
Advisory services on regulatory pathway selection (e.g., 505(b)(2), EU hybrid) and patent filing/portfolio management for printing-based dosage forms.
Operational support and partnerships to secure cGMP clinical and commercial production capacity for printed oral dosage forms.
Expertise Areas
- 3D screen-printed oral dosage form development
- Immediate, delayed, extended and pulsatile release formulation design
- Multi-compartment and sequential-release tablet architectures
- Paste formulation and rheology control for additive manufacturing
Key Technologies
- Screen-printing additive manufacturing (flatbed 3D screen printing)
- Multi-material / multi-layer printing
- Semi-solid paste formulation and rheology control
- CAD-driven geometry and SA/V design for release control
News & Updates
Planned attendance and asset showcase at BIO International Convention in Boston.
Hosting one-to-one meetings with pharmaceutical industry partners during DCAT Week to discuss printed dosage-form platform and partnership opportunities.
Planned participation at Jefferies Healthcare Conference in London.
Planned participation at BIO-Europe in Vienna.
Company post describing immediate- and delayed-release drug delivery concepts and how printing, excipient choice and geometry control can produce different release profiles.
Announcement and summary of a peer-reviewed study demonstrating proof-of-concept fabrication of delayed-release printed tablets, characterization (mass, hardness, friability, dissolution) and scalability considerations.
Planned attendance and asset showcase at BIO International Convention in Boston.
Hosting one-to-one meetings with pharmaceutical industry partners during DCAT Week to discuss printed dosage-form platform and partnership opportunities.
Planned participation at Jefferies Healthcare Conference in London.
Planned participation at BIO-Europe in Vienna.
Company post describing immediate- and delayed-release drug delivery concepts and how printing, excipient choice and geometry control can produce different release profiles.
Announcement and summary of a peer-reviewed study demonstrating proof-of-concept fabrication of delayed-release printed tablets, characterization (mass, hardness, friability, dissolution) and scalability considerations.